Intercytex Limited Starts Skin Graft Substitute Trial

LONDON (SHARECAST) - Intercytex enjoyed gains today as the cell therapy outfit focused on skin and hair regeneration said it has started a Phase I study to evaluate the safety and tolerability of skin graft substitute ICX-SKN.

MORE ON THIS TOPIC